Arimoclomol Impurities

Arimoclomol boosts the heat shock response, which is thought to increase protein breakdown and, as a result, lessens cell stress.

Show
per page
Impurity structure Parent Drug Name Name of Impurity Catalogue No. CAS No.
Racemic Arimoclomol Maleate Arimoclomol

Racemic Arimoclomol Maleate

VL6880001 289893-24-9
Racemic Arimoclomol-D10 Maleate Arimoclomol

Racemic Arimoclomol-D10 Maleate

DVE00162 N/A

Arimoclomol Related Compound

To treat amyotrophic lateral sclerosis (ALS), popularly known as Lou Gehrig’s disease, a neurodegenerative condition for which no effective therapy exists.

References

  • Kieran, Dairin, et al. Treatment with Arimoclomol, a Coinducer of Heat Shock Proteins, Delays Disease Progression in ALS Mice. no. 4, Mar. 2004, pp. 402–5, https://doi.org/10.1038/nm1021. Accessed 26 July 2023.
  • Kirkegaard, Tove, et al. Heat Shock Protein–Based Therapy as a Potential Candidate for Treating the Sphingolipidoses. no. 355, Sept. 2016, https://doi.org/10.1126/scitranslmed.aad9823. Accessed 26 July 2023.
  • “Arimoclomol Dosing, Indications, Interactions, Adverse Effects, and More.” Medscape.com, 13 Apr. 2023, reference.medscape.com/drug/arimoclomol-4000137#:~:text=Brand%20and%20Other%20Names%3A,Classes%3A%20Pharmacologic%20Chaperones. Accessed 26 July 2023.

FAQ

What is the mechanism of action of Arimoclomol?

Arimoclomol belongs to a class of heat shock protein-modulating drugs that act as co-inducers of heat shock proteins, particularly HSP70, and whose mechanism of action involves stabilizing the interaction of Heat Shock Factor 1 (HSF1) with Heat Shock Elements (HSEs), the transcriptional elements that control heat shock.

Arimoclomol belongs to what drug class?

Pharmacologic Chaperones are a class of Arimoclomol

What is the pharmacological action of arimoclomol?

Arimoclomol, a heat shock protein (HSP) inducer, considerably slows disease development in mice harboring a SOD1 mutant in which glycine is replaced with alanine at position 93 (SOD1(G93A)). SOD1(G93A) mice treated with arimoclomol demonstrate significant improvement in hind limb muscle function and motoneuron survival in the latter stages of the illness, resulting in a 22% increase in lifetime.